SULT2B1 was previously known to decrease serum and hepatic lipid levels by deactivating the oxysteroid-derivative endogenous LXR agonists (14), and inhibit gluconeogenesis by targeting HNF4α (15), both of which may have contributed to the alleviation of metabolic abnormalities in obesity. The gene discussed is SULT2B1; the disease is obesity disorder.